Leerink Swann began advantage on shares of ISIS Pharmaceuticals (NASDAQ:ISIS) in a abode appear on Friday. The close issued a bazaar accomplish appraisement and a $40.00 amount cold on the stock.
Shares of ISIS Pharmaceuticals (NASDAQ:ISIS) opened at 40.18 on Friday. ISIS Pharmaceuticals has a one year low of $22.25 and a one year aerial of $62.66. The banal has a 50-day affective boilerplate of $38.65 and a 200-day affective boilerplate of $34.39. The company's bazaar cap is $4.731 billion.
ISIS Pharmaceuticals (NASDAQ:ISIS) aftermost appear its balance abstracts on Monday, August 4th. The aggregation appear ($0.10) balance per allotment (EPS) for the quarter, assault the accord appraisal of ($0.12) by $0.02. The aggregation had acquirement of $57.08 actor for the quarter, compared to the accord appraisal of $45.60 million. During the aforementioned division in the antecedent year, the aggregation acquaint ($0.09) balance per share. The company's acquirement for the division was up 49.8% on a year-over-year basis. Analysts apprehend that ISIS Pharmaceuticals will column $-0.76 EPS for the accepted budgetary year.
Several added analysts accept additionally afresh commented on the stock. Analysts at BMO Capital Markets common an beat appraisement on shares of ISIS Pharmaceuticals in a analysis agenda on Thursday, August 28th. They now accept a $70.00 amount ambition on the stock. Separately, analysts at Laidlaw accomplished advantage on shares of ISIS Pharmaceuticals in a analysis agenda on Tuesday, August 12th. They set a buy appraisement on the stock. Finally, analysts at Laidlow & Co. accomplished advantage on shares of ISIS Pharmaceuticals in a analysis agenda on Tuesday, August 12th. They set a buy appraisement and a $52.00 amount ambition on the stock. One analysis analyst has rated the banal with a advertise rating, bristles accept accustomed a authority appraisement and six accept issued a buy appraisement to the company's stock. The aggregation currently has an boilerplate appraisement of Authority and a accord ambition amount of $45.30.
Receive Account & Ratings for ISIS Pharmaceuticals Daily - Enter your email abode beneath to accept a abridged circadian arbitrary of the latest account and analysts' ratings for ISIS Pharmaceuticals and accompanying companies with Analyst Ratings Network's FREE circadian email newsletter.
0 comments:
Post a Comment